Targeting DNA-LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity
Authors:
- Nicolas MarzoliniNMNicolas Marzolini
- Taylor V. BrysgelTBTaylor V. Brysgel
- Eno-Obong EssienEEEno-Obong Essien
- Ryan J. RahmanRRRyan J. Rahman
- Jichuan WuJWJichuan Wu
- Manthan N. PatelMPManthan N. Patel
- Sachchidanand TiwariSTSachchidanand Tiwari
- Carolann L. EspyCECarolann L. Espy
- Vladimir V. ShuvaevVSVladimir V. Shuvaev
- Elizabeth D. HoodEHElizabeth D. Hood
- Liam S. ChaseLCLiam S. Chase
Preprint
Abstract
DNA-lipid nanoparticles (DNA-LNPs) loaded with inhibitors of the cGAS-STING pathway enable safe and effective delivery of DNA in vivo . Herein, we report the first instances of extrahepatic DNA-LNP targeting. DNA-LNPs conjugated to antibodies against PECAM-1 or VCAM-1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM-targeted transgene expression increases over two weeks, resulting in markedly higher lung-to-liver expression ratios than our previous PECAM-targeted mRNA-LNPs. Off-target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half-life. We further improve this expression specificity by replacing full-length antibodies with Fab fragments. Single-cell analysis reveals a key mechanism underlying the improvements in organ-specificity: target organ expression is dominated by long-lived endothelial cells, while off-target liver delivery and expression are in non-endothelial cells with shorter half-lives. Collectively, these studies demonstrate that targeted DNA-LNPs achieve high levels of organ- and cell-type-specific transgene expression and thus provide a therapeutic platform for dozens of endothelial-centric diseases.Keywords
All Related Versions
- Published version: Advanced Science, 13 (14), e15480.
Funding Information
- National Science Foundation (DBI - 2400327)
- National Institutes of Health (RO1HL155106)
- National Institutes of Health (R01HL157189)
- National Institutes of Health (1DP5OD036159)
- National Institutes of Health (R01-HL-153510)
- National Institutes of Health (R01-HL160694)
- National Institutes of Health (R01-HL164594)
- U.S. National Library of Medicine (R01NS131279)
- American Heart Association (24PRE1195406)
This publication has 52 references indexed in Scilit:
- Endothelial dysfunction in acute ischemic stroke: a reviewJournal of Neurology, 2025
- Conjugation Chemistry Markedly Impacts Toxicity and Biodistribution of Targeted Nanoparticles, Mediated by Complement ActivationAdvanced Materials, 2024
- Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and SolutionsAdvanced Materials, 2024
- ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disordersClinica Chimica Acta, 2023
- The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungsJournal of Controlled Release, 2022
- Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle SizePharmaceutical Research, 2022
- Novel lipid combination for delivery of plasmid DNA to immune cells in the spleenJournal of Controlled Release, 2021
- PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptakeJournal of Controlled Release, 2018
- Isolation and Culture of Endothelial Cells from Large Vessels2017
- VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 2008